Superior Accuracy
Improve breast cancer detection1 and accurately identify women at high risk of developing breast cancer in the short term2,3
Breast AI provides cloud-native AI solutions for breast cancer detection, breast density measurement, and personalized risk assessment that offer clinically proven benefits to clinicians and patients, and are designed to optimize efficiency, enhance the patient experience, and improve outcomes.
Reduce reading time by as much as 52.7%1 with automated detection and analysis of DTB images which assists in prioritizing caseloads and clinical decision-making
Anytime, anywhere, access to results through a single user interface zero-footprint viewer and an internet connection - No on-premises hardware required
Simplify and standardize breast density stratification and reporting with accurate and reliable results
Breast AI offers a high-performing, concurrent read cancer detection and workflow solution that rapidly and accurately analyzes each DBT image detecting both malignant soft tissue densities and calcifications with unrivaled accuracy.1,4,5,6,7
This innovative solution provides radiologists with key information, such as Certainty of Finding lesion and Case Scores, which assists in prioritizing caseloads, clinical decision-making and may help to reduce physician burnout.
Get access to clinically proven benefits, including an 8% improvement in sensitivity, a 7% improvement in specificity, and a 52.7% reduction in reading time for radiologists.1
Breast AI leverages a deep learning algorithm for accurate automated breast density assessments on the Arterys platform. This solution simplifies and standardizes breast density stratification and reporting with accurate and reliable results.4,8
Using mammographic images, the algorithm analyzes the woman’s breast anatomy and categorizes her breast density within the appropriate BI-RADS® 5th edition density category.
Breast AI offers a clinical decision support tool that provides an accurate, personalized short-term breast cancer risk estimation for each woman.
This easy-to-implement solution uniquely combines a range of risk factors, offering superior performance in assessing short-term risk compared to traditional breast cancer risk models.2,3,4 Specifically designed to factor in racial and ethnic backgrounds, this solution offers an equitable and inclusive approach to precision screening.4
The algorithm also factors in clinically relevant global screening guidelines and more than 15 country incidence and mortality reference tables for alignment with that country’s general population.
Read some of the articles in prestigious publications that show the Breast AI Arterys solution addressing imaging advances and research.
Original Research: Eriksson, M et al. A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care. Science Translational Medicine. 2022; 14 (644).
Original Research: Eriksson M et al. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Radiology. 2020; 297(2): 327-333.
Arterys, a Tempus company, has announced a US and EU distribution agreement with Therapixel, a medical imaging software...
The 2023 Society of Breast Imaging (SBI) Breast Imaging Symposium is a must-attend event for radiologists and...
Arterys is proud to announce further adoption, growth, and partnerships, including a lineup with Amazon HealthLake...